Aldose reductase: A novel therapeutic target for inflammatory pathologies

Kota Ramana, Satish Srivastava

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

Aldose reductase (AR), that catalyzes the rate limiting step of the polyol pathway of glucose metabolism, besides reducing glucose to sorbitol, reduces a number of lipid peroxidation - derived aldehydes and their glutathione conjugates. Recent studies suggest that apart from its involvement in diabetic complications, AR's catalytic activity plays a key role in a number of inflammatory diseases such as atherosclerosis, sepsis, asthma, uveitis, and colon cancer. Furthermore, AR is overexpressed in human cancers such as liver, colon, breast, cervical and ovarian. Since AR inhibitors have already undergone up to phase-iii clinical trials for diabetic complications, they could be safe anti-inflammatory drugs. Therefore the future use of AR inhibitors in down-regulating major inflammatory pathologies such as cancer and cardiovascular diseases could relieve some of the major health concerns of worldwide.

Original languageEnglish (US)
Pages (from-to)17-20
Number of pages4
JournalInternational Journal of Biochemistry and Cell Biology
Volume42
Issue number1
DOIs
StatePublished - Jan 2010

Fingerprint

Aldehyde Reductase
Pathology
Diabetes Complications
Glucose
Sorbitol
Uveitis
Therapeutics
Metabolism
Aldehydes
Liver
Colonic Neoplasms
Lipid Peroxidation
Glutathione
Catalyst activity
Neoplasms
Sepsis
Atherosclerosis
Colon
Breast
Anti-Inflammatory Agents

Keywords

  • Aldehydes
  • Aldose reductase
  • Inflammation
  • NF-κB
  • Oxidative stress

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology

Cite this

Aldose reductase : A novel therapeutic target for inflammatory pathologies. / Ramana, Kota; Srivastava, Satish.

In: International Journal of Biochemistry and Cell Biology, Vol. 42, No. 1, 01.2010, p. 17-20.

Research output: Contribution to journalArticle

@article{011a999abe684876a11fe6a85749b43f,
title = "Aldose reductase: A novel therapeutic target for inflammatory pathologies",
abstract = "Aldose reductase (AR), that catalyzes the rate limiting step of the polyol pathway of glucose metabolism, besides reducing glucose to sorbitol, reduces a number of lipid peroxidation - derived aldehydes and their glutathione conjugates. Recent studies suggest that apart from its involvement in diabetic complications, AR's catalytic activity plays a key role in a number of inflammatory diseases such as atherosclerosis, sepsis, asthma, uveitis, and colon cancer. Furthermore, AR is overexpressed in human cancers such as liver, colon, breast, cervical and ovarian. Since AR inhibitors have already undergone up to phase-iii clinical trials for diabetic complications, they could be safe anti-inflammatory drugs. Therefore the future use of AR inhibitors in down-regulating major inflammatory pathologies such as cancer and cardiovascular diseases could relieve some of the major health concerns of worldwide.",
keywords = "Aldehydes, Aldose reductase, Inflammation, NF-κB, Oxidative stress",
author = "Kota Ramana and Satish Srivastava",
year = "2010",
month = "1",
doi = "10.1016/j.biocel.2009.09.009",
language = "English (US)",
volume = "42",
pages = "17--20",
journal = "International Journal of Biochemistry and Cell Biology",
issn = "1357-2725",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Aldose reductase

T2 - A novel therapeutic target for inflammatory pathologies

AU - Ramana, Kota

AU - Srivastava, Satish

PY - 2010/1

Y1 - 2010/1

N2 - Aldose reductase (AR), that catalyzes the rate limiting step of the polyol pathway of glucose metabolism, besides reducing glucose to sorbitol, reduces a number of lipid peroxidation - derived aldehydes and their glutathione conjugates. Recent studies suggest that apart from its involvement in diabetic complications, AR's catalytic activity plays a key role in a number of inflammatory diseases such as atherosclerosis, sepsis, asthma, uveitis, and colon cancer. Furthermore, AR is overexpressed in human cancers such as liver, colon, breast, cervical and ovarian. Since AR inhibitors have already undergone up to phase-iii clinical trials for diabetic complications, they could be safe anti-inflammatory drugs. Therefore the future use of AR inhibitors in down-regulating major inflammatory pathologies such as cancer and cardiovascular diseases could relieve some of the major health concerns of worldwide.

AB - Aldose reductase (AR), that catalyzes the rate limiting step of the polyol pathway of glucose metabolism, besides reducing glucose to sorbitol, reduces a number of lipid peroxidation - derived aldehydes and their glutathione conjugates. Recent studies suggest that apart from its involvement in diabetic complications, AR's catalytic activity plays a key role in a number of inflammatory diseases such as atherosclerosis, sepsis, asthma, uveitis, and colon cancer. Furthermore, AR is overexpressed in human cancers such as liver, colon, breast, cervical and ovarian. Since AR inhibitors have already undergone up to phase-iii clinical trials for diabetic complications, they could be safe anti-inflammatory drugs. Therefore the future use of AR inhibitors in down-regulating major inflammatory pathologies such as cancer and cardiovascular diseases could relieve some of the major health concerns of worldwide.

KW - Aldehydes

KW - Aldose reductase

KW - Inflammation

KW - NF-κB

KW - Oxidative stress

UR - http://www.scopus.com/inward/record.url?scp=70749089191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70749089191&partnerID=8YFLogxK

U2 - 10.1016/j.biocel.2009.09.009

DO - 10.1016/j.biocel.2009.09.009

M3 - Article

C2 - 19778627

AN - SCOPUS:70749089191

VL - 42

SP - 17

EP - 20

JO - International Journal of Biochemistry and Cell Biology

JF - International Journal of Biochemistry and Cell Biology

SN - 1357-2725

IS - 1

ER -